FAKHRAVAC

{{short description|Vaccine against COVID-19}}

{{Use dmy dates|date=June 2021}}

{{Infobox drug

| Verifiedfields =

| verifiedrevid =

| drug_name =

| INN =

| type = vaccine

| image = FakhraVac vaccine 01 (cropped).jpg

| alt =

| caption = A vial of FakhraVac

| target = SARS-CoV-2

| vaccine_type = inactivated

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_EU =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_UK =

| legal_US =

| legal_UN =

| legal_NZ =

| legal_status = Emergency use authorization: {{abbr|IRN|Iran}}

| routes_of_administration = Intramuscular

| CAS_number =

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms = Fakhra, MIVAC

}}

{{COVID-19 pandemic sidebar}}

FAKHRAVAC ({{langx|fa|واکسن فخرا}}) is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research,{{cite news | vauthors = Motamedi M |title=Iran starts human trials of its third domestic COVID vaccine |url=https://www.aljazeera.com/news/2021/3/16/iran-starts-human-trials-on-third-locally-developed-vaccine |publisher=Al Jazeera |date=16 March 2021}} a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials.{{Cite web |title=Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial |url=https://en.irct.ir/trial/54133 |website=en.irct.ir |publisher=Iran Registry of Clinical Trials |access-date=21 March 2021 }}{{Cite web |title=Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial |url=https://en.irct.ir/trial/56027 |website=en.irct.ir |publisher=Iran Registry of Clinical Trials |access-date=15 June 2021 }} It is currently in phase III.{{Cite web|title=Iran Authorizes Emergency Use of Third Homegrown Vaccine - Defense news|url=https://www.tasnimnews.com/en/news/2021/09/09/2568712/iran-authorizes-emergency-use-of-third-homegrown-vaccine|access-date=2021-09-09|website=Tasnim News Agency|language=en}} It received emergency use authorization in Iran on 9 September 2021.

The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh. According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran.{{Cite web|date=28 November 2020|title=Research center run by Fakhrizadeh produced first COVID-19 test kits for Iranians: Defense minister|url=https://parstoday.com/en/news/iran-i130017|url-status=live|archive-url=https://web.archive.org/web/20201205205346/https://parstoday.com/en/news/iran-i130017-research_center_run_by_fakhrizadeh_produced_first_covid_19_test_kits_for_iranians_defense_minister|archive-date=5 December 2020|access-date=7 September 2021|website=Pars Today}} Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.[https://www.inss.org.il/publication/fakhrizadeh/ The Assassination of Fakhrizadeh: Considerations and Consequences]